Central Sleep Apnea Treatment without CPAP

Central sleep apnea treatment without CPAP includes adaptive servo-ventilation, transvenous phrenic nerve stimulation, medications like acetazolamide, positional therapy, and targeted treatment of underlying conditions such as heart disease or opioid pain medications use. Unlike obstructive sleep apnea, central sleep apnea originates in the brainstem rather than a blocked airway, which means CPAP therapy alone often fails to resolve it and can even make it worse. According to the American Academy of Sleep Medicine, central sleep apnea makes up a small minority of sleep apnea cases, yet its treatment demands a fundamentally different clinical approach. This guide is for anyone diagnosed with central sleep apnea who struggles with CPAP, their care partners, and clinicians evaluating non-CPAP pathways. You will find a full breakdown of every alternative treatment, how each works, who each is best for, realistic limitations, and how sleep-driven biomarker tracking through Dumbo Health connects central sleep apnea management to long-term biological aging outcomes.

Quick Answer

Central sleep apnea treatment without CPAP relies on addressing the brain's faulty respiratory signaling rather than splinting an airway open. Proven alternatives include adaptive servo-ventilation, transvenous phrenic nerve stimulation via the Remede System, medications such as acetazolamide, supplemental oxygen, positional therapy, and treating the root cause when central apneas stem from heart failure, opioid pain medications, or high-altitude exposure. The right option depends on whether hypocapnia, Cheyne-Stokes respiration, or medication-induced central apnea is driving the events. Dumbo Health helps track how central sleep apnea and its treatments affect biological aging through longitudinal biomarker testing and the SleepLongevityAge metric.

Key Takeaways

• Central sleep apnea is a brainstem-driven sleep disorder in which the brain intermittently fails to send respiratory effort signals, unlike obstructive sleep apnea where the airway physically collapses.
• CPAP therapy can worsen central apneas in some patients by lowering carbon dioxide below the apneic threshold, a phenomenon called complex sleep apnea or treatment-emergent central sleep apnea.
• Adaptive servo-ventilation is the most effective non-CPAP positive airway pressure device for central sleep apnea but is contraindicated in patients with heart failure and an ejection fraction below 45 percent.
• The Remede System, an FDA-approved implantable transvenous phrenic nerve stimulation device, cut the Apnea-Hypopnea Index by at least half in about half of treated patients in its pivotal trial, compared with about 1 in 10 in the control group.
• Acetazolamide, a carbonic anhydrase inhibitor, stabilizes breathing by increasing CO2 reserve, though it requires physician monitoring for metabolic side effects.
• Dumbo Health's Core membership tracks 51 sleep-longevity biomarkers twice a year for $0.99 a day, giving people with central sleep apnea longitudinal data on how treatment is affecting cardiovascular, metabolic, and inflammatory markers tied to biological aging.

Why Central Sleep Apnea Requires Different Treatment Than Obstructive Sleep Apnea

Central sleep apnea and obstructive sleep apnea share a name but have fundamentally different mechanisms, which is why the same treatment rarely works for both. In obstructive sleep apnea, the soft palate, tongue, and surrounding tissues collapse during sleep, physically blocking airflow despite ongoing respiratory effort. Continuous Positive Airway Pressure solves that problem by delivering pressurized air pressure to hold the airway open.

Central sleep apnea, by contrast, involves no airway obstruction at all. The brainstem temporarily stops sending motor signals to the respiratory muscles, so the lungs simply do not attempt to breathe. According to the National Heart, Lung, and Blood Institute, this lapse in respiratory effort is what distinguishes central from obstructive events on a sleep study.

The Role of Carbon Dioxide and the Apneic Threshold

The respiratory chemoreflex is the feedback loop between blood carbon dioxide levels and breathing drive. When carbon dioxide rises, chemoreceptors in the brainstem signal the respiratory muscles to breathe harder. When carbon dioxide falls below a critical level called the apneic threshold, the brain may stop sending those signals entirely.

In many central sleep apnea patients, particularly those with Cheyne-Stokes respiration linked to heart failure, the CO2 reserve between the normal waking level and the apneic threshold is abnormally narrow. Even small ventilatory responses to arousals can push end-tidal CO2 below the threshold, triggering a central apnea. This explains why CPAP, which increases ventilation and can lower carbon dioxide further, sometimes creates or worsens central apneas rather than resolving them.

This condition, known as complex sleep apnea or treatment-emergent central sleep apnea, affects an estimated 5 to 15 percent of patients initially diagnosed with obstructive sleep apnea who are placed on CPAP, according to research published in the Sleep Foundation's clinical review of treatment-emergent central apnea.

Hypocapnic Central Sleep Apnea Syndromes

Hypocapnia, or abnormally low blood carbon dioxide, sits at the center of many central sleep apnea presentations. Hypocapnic central sleep apnea syndromes include idiopathic central sleep apnea, high-altitude periodic breathing, and Cheyne-Stokes breathing. Each shares a common thread: the ventilatory responses overshoot, CO2 drops below the apneic threshold, breathing stops, CO2 climbs again, and the cycle repeats.

This oscillating pattern, visible on polysomnography as a crescendo-decrescendo breathing pattern, is the hallmark of Cheyne-Stokes respiration. It is most common in patients with heart failure, stroke, or renal failure, and its presence on a sleep study signals that standard CPAP is unlikely to be the right first-line therapy.

DID YOU KNOW: According to the Cleveland Clinic, Cheyne-Stokes breathing occurs in up to 50 percent of patients with moderate to severe heart failure, making it one of the most common yet under-recognized central sleep apnea triggers.

KEY TAKEAWAY: Central sleep apnea is driven by unstable respiratory signaling in the brainstem, not airway collapse, which means treatments must stabilize the chemoreflex loop rather than simply push air into the airway.

Understanding this mechanism is what makes choosing the right non-CPAP treatment possible, starting with the most studied device-based alternatives.

Adaptive Servo-Ventilation: The Leading Non-CPAP Device for Central Sleep Apnea

Adaptive servo-ventilation is the most effective positive airway pressure alternative to CPAP for central sleep apnea, but it comes with a critical safety restriction that every patient and prescribing physician must understand.

How Adaptive Servo-Ventilation Works

Adaptive servo-ventilators continuously monitor the patient's airflow and respiratory effort on a breath-by-breath basis. When the device detects a central apnea or hypopnea, it delivers a variable pressure support boost through a mask, essentially breathing for the patient during the pause. Between events, it scales support back to a minimal level, preventing the over-ventilation that CPAP often causes.

This dynamic approach directly addresses the unstable ventilatory responses that define central sleep apnea. Unlike standard CPAP or Bilevel Positive Airway Pressure, which deliver fixed or semi-fixed air pressure, adaptive servo-ventilation modulates pressure in real time to keep carbon dioxide above the apneic threshold.

The SERVE-HF Safety Warning

In 2015, the landmark SERVE-HF trial found that adaptive servo-ventilation increased cardiovascular mortality in patients with heart failure and a left ventricular ejection fraction of 45 percent or less combined with predominant central sleep apnea. The Food and Drug Administration subsequently updated labeling to contraindicate adaptive servo-ventilation in this population.

If you have heart failure with reduced ejection fraction, adaptive servo-ventilation may increase your risk of death. A cardiologist and Sleep Medicine specialist must evaluate your ejection fraction before this therapy is prescribed.

This is not a minor caveat. Because Cheyne-Stokes respiration and heart disease so frequently co-occur, a significant portion of central sleep apnea patients are ineligible for adaptive servo-ventilation. For those patients, other alternatives covered later in this guide, such as transvenous phrenic nerve stimulation, medications, or optimization of cardiac treatment, become essential.

Who Is a Good Candidate for Adaptive Servo-Ventilation

Adaptive servo-ventilation remains the standard treatment for:

• Idiopathic central sleep apnea
• Treatment-emergent complex sleep apnea that persists after CPAP titration
• Central sleep apnea related to opioid pain medications (in some protocols)
• Cheyne-Stokes respiration in patients with heart failure and preserved ejection fraction (above 45 percent)

Sleep specialists typically order a titration polysomnography to calibrate the pressure settings before a patient takes the device home.

KEY TAKEAWAY: Adaptive servo-ventilation is the most targeted non-CPAP positive airway pressure device for central sleep apnea, but it is contraindicated in heart failure with reduced ejection fraction below 45 percent, making a thorough cardiac evaluation essential before prescription.

For patients who cannot use any mask-based positive airway pressure device, implantable nerve-stimulation devices offer a fundamentally different approach.

Transvenous Phrenic Nerve Stimulation: The Remede System

Transvenous phrenic nerve stimulation is the only FDA-cleared implantable treatment specifically for central sleep apnea. The Remede System is the device that delivers this therapy, and it represents a genuine non-mask, non-airway-pressure option for patients who fail or cannot tolerate PAP machines.

How the Remede System Works

The Remede System is surgically implanted in a procedure similar to a cardiac pacemaker insertion. A pulse generator placed in the chest sends electrical impulses through a transvenous lead to the phrenic nerve, which controls the diaphragm. During sleep, the device stimulates the diaphragm to contract rhythmically, maintaining respiratory effort even when the brainstem fails to send its own signals.

According to a pivotal trial published and reviewed by the Food and Drug Administration, about half of patients treated with the Remede System had their Apnea-Hypopnea Index cut by at least 50 percent at 6 months, compared with about 1 in 10 in the control group, along with improvements in oxygen levels and sleep quality.

Candidacy and Limitations

Transvenous phrenic nerve stimulation is generally reserved for patients who:

• Have moderate to severe central sleep apnea confirmed on polysomnography
• Have failed or cannot tolerate CPAP, adaptive servo-ventilation, or other positive airway pressure devices
• Do not have active infection or anatomy that prevents safe lead placement

The procedure requires a cardiac electrophysiologist or thoracic surgeon and is performed in a hospital or surgical center. Recovery is typically brief, but the device requires periodic programming adjustments and monitoring, much like a pacemaker.

Insurance coverage for the Remede System varies. Many commercial insurers and Medicare have coverage pathways, but prior authorization is common and approval timelines can be lengthy.

DID YOU KNOW: The Remede System was the first and remains the only FDA-cleared neurostimulation device designed specifically for central sleep apnea, distinct from hypoglossal nerve stimulation devices like Inspire therapy, which are approved only for obstructive sleep apnea.

KEY TAKEAWAY: The Remede System uses transvenous phrenic nerve stimulation to restore diaphragmatic contraction during sleep, offering a mask-free option for moderate to severe central sleep apnea patients who cannot use positive airway pressure devices.

Surgical and device-based therapies address the physical mechanism, but pharmacological approaches target the chemical imbalance at the root of many central apneas.

Medications for Central Sleep Apnea: Acetazolamide and Beyond

Acetazolamide is the most studied medication for central sleep apnea, though several other pharmacological approaches target the respiratory chemoreflex through different pathways.

Acetazolamide and Carbonic Anhydrase Inhibition

Acetazolamide is a carbonic anhydrase inhibitor that causes a mild metabolic acidosis. This shifts the blood's acid-base balance, effectively lowering the apneic threshold. With more room between the resting carbon dioxide level and the point at which breathing stops, the unstable oscillations that produce central apneas become less likely.

Studies reviewed by the American Academy of Sleep Medicine have shown that acetazolamide reduces the Apnea-Hypopnea Index in central sleep apnea, particularly in high-altitude periodic breathing and idiopathic central sleep apnea. The effect on Cheyne-Stokes respiration in heart failure is more variable and less consistently recommended.

Common side effects include tingling in the fingers and toes (paresthesia), taste changes, increased urination, and metabolic disturbances. Because it alters blood chemistry, regular lab monitoring of bicarbonate, potassium, and kidney function is needed. That monitoring should be ordered by the doctor who prescribes acetazolamide, on the schedule they set. Dumbo Health's Core membership tests metabolic markers twice a year for longer-term tracking, but it is not a substitute for medication safety labs.

Other Medications and Pharmacological Approaches

Beyond acetazolamide, several other pharmacological strategies have been studied for central sleep apnea:

• Theophylline: A respiratory stimulant that increases ventilatory drive. It has shown modest benefit in small studies but carries a narrow therapeutic window and cardiac side effects, limiting its clinical use.
• Oxygen therapy: While not a medication in the traditional sense, supplemental oxygen at low flow rates (2 to 3 liters per minute) can reduce central apneas by preventing the oxygen desaturation that triggers arousal and the subsequent ventilatory overshoot. According to the American Academy of Sleep Medicine, supplemental oxygen is a recognized option for central sleep apnea, particularly when hypoxemia is prominent.
• Opioid reduction or rotation: When central sleep apnea is caused by opioid pain medications, the most direct treatment is dose reduction or switching to an opioid with less respiratory depression, though this requires close coordination with pain management specialists.

Emerging Pharmacological Targets

Researchers are exploring chemoreflex modulation as a more precise pharmacological approach. The goal is to develop drugs that specifically widen the CO2 reserve or stabilize the respiratory chemoreflex loop without the systemic side effects of current options. As of 2026, no chemoreflex-specific drug is FDA-cleared for central sleep apnea, but clinical interest in this area is growing.

KEY TAKEAWAY: Acetazolamide is the most established medication for central sleep apnea, working through carbonic anhydrase inhibition to stabilize CO2 levels, but it requires ongoing metabolic monitoring that structured biomarker testing can support.

Medications and devices address the physiology, but many central sleep apnea cases improve most when the underlying condition driving the apneas is treated directly.

Treating the Underlying Cause: Heart Failure, Opioids, and Other Root Triggers

The most effective central sleep apnea treatment is often not a sleep treatment at all. Resolving or stabilizing the condition that destabilized breathing in the first place can reduce or eliminate central apneas without any dedicated sleep-specific intervention.

Heart Failure Optimization

Heart failure is the single most common cause of Cheyne-Stokes respiration and central sleep apnea. The mechanism involves rostral fluid shift: when a patient lies down, fluid redistributes from the legs toward the chest and neck, increasing pulmonary congestion and sensitizing the respiratory chemoreflex. Cardiologists treating the heart failure with guideline-directed medical therapy, including diuretics, beta-blockers, ACE inhibitors, and newer agents, often see central apnea events decrease as cardiac function improves.

According to the National Heart, Lung, and Blood Institute, treating the underlying heart disease is a foundational step in managing Cheyne-Stokes breathing, and sleep-specific therapies should complement rather than replace cardiac optimization.

Cardiac resynchronization therapy and left ventricular assist devices have also been shown to reduce central apneas in advanced heart failure, further reinforcing that addressing the heart often addresses the sleep disorder.

Opioid-Induced Central Sleep Apnea

Opioid pain medications suppress respiratory motor outputs in the brainstem, producing central apneas that can be severe. The Apnea-Hypopnea Index in opioid users often includes a mix of central and obstructive events, sometimes classified as mixed apnea. The most direct treatment is opioid dose reduction or discontinuation when clinically safe.

When opioid continuation is medically necessary, adaptive servo-ventilation (if ejection fraction allows) or BiPAP with a backup rate can help maintain respiratory effort during sleep. Neurologists and pain management specialists play a key role in balancing pain control with respiratory safety.

Other Treatable Causes

Additional root causes of central sleep apnea include:

• Stroke or brainstem lesions that damage respiratory control centers
• Renal failure, which alters blood chemistry and can destabilize the chemoreflex
• High-altitude exposure, where low oxygen and compensatory hyperventilation widen the gap between waking and sleeping CO2 levels
• Hypothyroidism, which can suppress respiratory drive

Each of these conditions has its own treatment pathway, and improvement in the underlying condition frequently reduces the central Apnea-Hypopnea Index without any PAP device or sleep medication.

KEY TAKEAWAY: Treating the root cause of central sleep apnea, whether heart failure, opioid use, or another medical condition, is often more effective than layering on sleep-specific devices, and it should be the first step in any personalized treatment plan.

With root causes addressed, many patients still benefit from behavioral and positional strategies that further reduce central events.

Behavioral and Positional Strategies for Central Sleep Apnea

Positional therapy and sleep schedule optimization offer low-risk, no-device approaches that can reduce central apnea severity, particularly as adjuncts to other treatments.

Positional Therapy and Body Position Manipulation

Positional therapy involves manipulating body position during sleep to reduce apnea events. In obstructive sleep apnea, sleeping on the side rather than the back reduces airway obstruction caused by gravitational collapse of the tongue and soft palate. In central sleep apnea, positional effects are less dramatic but still relevant.

Sleeping with the head and torso elevated (30 to 45 degrees) can reduce rostral fluid shift in heart failure patients, decreasing pulmonary congestion and stabilizing the respiratory chemoreflex. Cleveland Clinic notes that elevating the head of the bed is a common non-pharmacological recommendation for patients with both heart failure and Cheyne-Stokes breathing.

Body position manipulation using wedge pillows or adjustable beds is simple, carries no side effects, and can be started immediately. It does not replace definitive treatment but can meaningfully reduce central apnea events in patients with fluid-mediated mechanisms.

Sleep Schedule and Circadian Rhythm Optimization

Fragmented sleep itself destabilizes breathing. Sleep fragmentation increases arousals, each arousal triggers a ventilatory overshoot, and each overshoot can push carbon dioxide below the apneic threshold. Improving sleep hygiene, maintaining a consistent sleep schedule, and maximizing slow wave sleep (the deepest, most stable phase of sleep from a respiratory standpoint) can reduce the frequency of central events.

The Sleep Foundation recommends maintaining a consistent bedtime and wake time within 30 minutes each day, avoiding stimulants after mid-afternoon, and keeping the sleep environment cool and dark to support deeper, less fragmented sleep.

Weight Reduction and Metabolic Health

Obesity worsens both obstructive and central sleep apnea through overlapping mechanisms. Excess weight around the chest wall reduces lung volumes, increases the work of breathing, and destabilizes the CO2 set point. Weight reduction, whether through dietary changes, medical management (including newer GLP-1 medications like Zepbound), or Bariatric surgery, can improve the Apnea-Hypopnea Index across all sleep apnea types.

The connection between metabolic health and sleep-breathing stability is exactly why Dumbo Health's biomarker testing approach includes metabolic markers like HbA1c and inflammatory markers like hs-CRP. Tracking these over time shows whether weight loss, medication adjustments, or lifestyle changes are actually moving the metabolic needle in a direction that supports respiratory stability during sleep.

KEY TAKEAWAY: Positional therapy, sleep schedule consistency, and weight reduction are low-risk strategies that support central sleep apnea treatment by reducing the triggers, such as fluid shifts, arousals, and metabolic instability, that destabilize breathing during sleep.

Beyond behavioral strategies, several device-based alternatives fall between PAP machines and surgery.

Non-PAP Devices: Oral Appliances, Nerve Stimulation, and EPAP Devices

Non-PAP devices developed primarily for obstructive sleep apnea have limited but occasionally relevant roles in central sleep apnea, and understanding those boundaries prevents wasted time and money.

Oral Appliances and Mandibular Advancement Devices

Oral Appliance Therapy uses a custom-fitted dental device to advance the lower jaw (mandibular advancement), pulling the tongue forward and opening the airway. Mandibular Advancement Devices are first-line alternatives to CPAP for mild to moderate obstructive sleep apnea and snoring. The American Academy of Sleep Medicine recommends them when CPAP is not tolerated.

However, Mandibular Advancement Devices address airway obstruction, not brainstem signaling. In pure central sleep apnea, where there is no airway collapse, an oral appliance will not resolve the apneas. In mixed apnea, where both obstructive and central events occur, a Mandibular Advancement Device may reduce the obstructive component while leaving central events unaffected.

Tongue Retaining Devices work differently, holding the tongue forward by suction rather than advancing the jaw, but they share the same limitation: they treat airway anatomy, not respiratory drive.

Hypoglossal Nerve Stimulation (Inspire Therapy)

Inspire therapy delivers hypoglossal nerve stimulation through an implanted device that activates the tongue muscles to prevent airway collapse during inspiration. Inspire is FDA-cleared for moderate to severe obstructive sleep apnea in patients who cannot tolerate CPAP.

Inspire therapy does not address central sleep apnea. The hypoglossal nerve controls tongue movement, not diaphragmatic contraction. This is a critical distinction that patients sometimes miss when researching surgical treatments for sleep apnea. The device to compare for central apnea is the Remede System (phrenic nerve stimulation), not Inspire (hypoglossal nerve stimulation).

EPAP Devices, Provent Therapy, and Bongo Rx

Expiratory Positive Airway Pressure devices like Provent Therapy and Bongo Rx create resistance during exhalation through one-way valves placed over the nostrils. This nasal expiratory resistance generates a small amount of positive airway pressure that helps keep the airway open.

These EPAP devices are designed for obstructive sleep apnea and snoring. Because they work by maintaining airway patency rather than stimulating respiratory effort, they have no established role in central sleep apnea treatment.

Enhanced Expiratory Rebreathing Space (EERS)

Enhanced Expiratory Rebreathing Space is an experimental approach that adds dead space to the breathing circuit, causing the patient to rebreathe a small amount of exhaled carbon dioxide. This raises the CO2 level and helps keep it above the apneic threshold. Early studies have shown that EERS can reduce central apnea events in Cheyne-Stokes respiration, but it is not commercially available as a standard treatment and remains largely investigational.

Oral Pressure Therapy and Winx

Oral Pressure Therapy, delivered through the Winx device, applies negative pressure inside the mouth to pull the soft palate forward and stabilize the airway. Like oral appliances, Winx targets airway obstruction rather than central respiratory drive. Its utility in central sleep apnea is not established, and the device has had limited commercial availability.

DID YOU KNOW: Phenotyping sleep apnea, which means identifying whether a patient's apneas are driven by anatomical airway obstruction, respiratory chemoreflex instability, arousal threshold, or muscle responsiveness, is increasingly recognized as essential for matching the right treatment to the right patient. Phenotypic traits determine whether devices that target the airway, the nerve, or the brain's breathing signal are most appropriate.

KEY TAKEAWAY: Oral appliances, EPAP devices, and hypoglossal nerve stimulation are effective for obstructive sleep apnea but do not treat the brainstem signaling failure behind central sleep apnea, making accurate diagnosis the most important step before choosing any device.

Knowing what works and what does not work leads to the practical question of how to build a treatment plan.

How to Build a Personalized Central Sleep Apnea Treatment Plan

A personalized treatment plan for central sleep apnea starts with an accurate diagnosis of the type and cause of your central apneas, then layers treatments based on severity, underlying conditions, and personal tolerability.

Step-by-Step Process for Getting Diagnosed and Treated

1. Complete an in-lab polysomnography (sleep study) that differentiates central, obstructive, and mixed apnea events and measures the Apnea-Hypopnea Index, oxygen desaturation, respiratory effort, and sleep architecture including slow wave sleep and sleep efficiency. A home sleep apnea test can screen for obstructive events, but polysomnographic recognition of central apneas generally requires in-lab monitoring with respiratory effort sensors, electrocardiogram leads, and brain activity channels.
2. Work with a Sleep Medicine specialist, and when applicable a cardiologist or neurologist, to identify the underlying cause. If heart failure is present, obtain an echocardiogram to determine ejection fraction. If opioid pain medications are involved, coordinate with pain management. If the central apneas emerged after starting CPAP (complex sleep apnea), document the treatment-emergent pattern.
3. Address the root cause first. Optimize heart failure medications, reduce opioids if safe, treat hypothyroidism, or descend from altitude. Reassess the Apnea-Hypopnea Index after root-cause treatment has been stabilized.
4. Select the most appropriate sleep-specific therapy based on the remaining central apnea burden. If ejection fraction is above 45 percent or no heart failure is present, adaptive servo-ventilation is typically first-line. If ejection fraction is below 45 percent, consider supplemental oxygen, acetazolamide, or transvenous phrenic nerve stimulation via the Remede System.
5. Implement behavioral and positional strategies as adjuncts. Elevate the head of bed, maintain a consistent sleep schedule, and pursue weight reduction if obesity is present.
6. Establish a longitudinal monitoring plan with repeat sleep studies and biomarker testing. Track whether treatment is reducing central events, improving oxygen levels, and moving metabolic and cardiovascular markers in the right direction.
7. Take the free Dumbo Health sleep quiz to see where to start, then use the Core or Concierge membership to set a biomarker baseline and track how your sleep is affecting your biological age over time.

After completing these steps, you have a treatment framework that is cause-specific, severity-matched, and measurable over time rather than a one-size-fits-all prescription.

Checklist Before Starting Non-CPAP Central Sleep Apnea Treatment

• Confirm central sleep apnea diagnosis with in-lab polysomnography, not just a home screening test
• Verify the type: idiopathic, Cheyne-Stokes respiration, opioid-induced, high-altitude, or treatment-emergent complex sleep apnea
• Obtain cardiac evaluation including ejection fraction before considering adaptive servo-ventilation
• Review all current medications with your physician, especially opioid pain medications and sedatives
• Ask your Sleep Medicine specialist whether your central apneas have an obstructive component (mixed apnea) that also needs treatment
• Confirm insurance coverage and prior authorization requirements for any prescribed device or procedure
• Set up baseline biomarker testing to monitor the metabolic and cardiovascular markers most affected by central sleep apnea and its treatment
• Take the free Dumbo Health sleep quiz to see whether biomarker testing is a good next step

KEY TAKEAWAY: A personalized treatment plan for central sleep apnea layers root-cause treatment, device or medication therapy, behavioral strategies, and longitudinal biomarker tracking to address both the sleep disorder and its downstream biological aging effects.

Even with the right plan, certain limitations and risks can affect outcomes.

Limitations and Risks of Non-CPAP Central Sleep Apnea Treatments

No central sleep apnea treatment is universally effective, and each alternative carries specific risks and limitations that patients and clinicians must weigh honestly.

Adaptive Servo-Ventilation: Mortality Risk in Heart Failure

The most serious limitation in the non-CPAP landscape is the SERVE-HF finding that adaptive servo-ventilation increased all-cause and cardiovascular mortality in heart failure patients with ejection fraction at or below 45 percent. This means the single most effective device for central sleep apnea is off-limits for the population that most commonly develops Cheyne-Stokes respiration. For these patients, alternative strategies such as cardiac optimization, supplemental oxygen, and the Remede System must fill the gap.

Remede System: Surgical Risks and Limited Availability

Transvenous phrenic nerve stimulation requires a surgical implantation with risks including infection, lead displacement, and device malfunction. Not all sleep centers or electrophysiology labs offer the procedure, and insurance approval can be slow. The device also requires ongoing follow-up for programming and battery replacement. Clinicians who are not familiar with the Remede System may not consider it, leaving some eligible patients without access.

Acetazolamide: Metabolic Side Effects and Off-Label Use

Acetazolamide is not FDA-approved specifically for central sleep apnea. Its use for this indication is off-label, which means insurance may not cover it, and dosing protocols vary between providers. Side effects such as metabolic acidosis, kidney stone risk, and electrolyte imbalances require periodic lab work. Your prescribing doctor should order and review these labs; a twice-yearly wellness panel does not replace them.

Supplemental Oxygen: Partial Effectiveness

Low-flow supplemental oxygen can reduce central apneas and improve oxygen levels, but it does not always normalize the Apnea-Hypopnea Index completely. In some patients, it may prolong apnea duration by removing the oxygen desaturation trigger for arousal, potentially worsening carbon dioxide retention. It is generally considered an adjunct, not a standalone cure.

Behavioral Strategies: Supportive but Rarely Sufficient Alone

Positional therapy, sleep schedule optimization, and weight reduction improve central sleep apnea but rarely eliminate it as a standalone treatment in moderate to severe cases. They work best as part of a layered plan rather than a replacement for device or pharmacological therapy.

Diagnostic Access

Accurate phenotyping of sleep apnea, distinguishing central from obstructive from mixed apnea, and identifying phenotypic traits like loop gain and arousal threshold, requires in-lab polysomnography with experienced scoring. Not all sleep centers routinely score central events in detail, and misclassification can lead to inappropriate treatment. Patients in areas with limited Sleep Medicine access may face long wait times or travel requirements.

KEY TAKEAWAY: Every non-CPAP central sleep apnea treatment has specific limitations, from the mortality risk of adaptive servo-ventilation in heart failure to the off-label status of acetazolamide and the surgical requirements of the Remede System, making informed, physician-guided selection essential.

Understanding these tradeoffs is easier when you see how they play out in real people's lives.

Real-World Scenarios: How Non-CPAP Treatment Looks in Practice

Common Scenarios

A 62-year-old retired teacher with congestive heart failure and an ejection fraction of 35 percent was diagnosed with severe central sleep apnea and Cheyne-Stokes respiration on polysomnography. Her cardiologist and Sleep Medicine specialist agreed that adaptive servo-ventilation was contraindicated due to the SERVE-HF findings. Instead, her treatment plan focused on aggressive cardiac optimization with guideline-directed medical therapy, supplemental oxygen at 2 liters per minute during sleep, head-of-bed elevation to reduce rostral fluid shift, and a referral to evaluate candidacy for the Remede System. Over six months, her cardiac medications were titrated, her central Apnea-Hypopnea Index improved from 38 to 14, and her daytime sleepiness resolved meaningfully. She enrolled in Dumbo Health's Core membership to track inflammatory markers (hs-CRP) and cardiovascular markers (ApoB, NT-proBNP via the Cardiac Strain add-on pack) alongside her cardiologist visits, creating a longitudinal record of how both her heart failure treatment and her central sleep apnea management were affecting her biological aging trajectory.

A 48-year-old software engineer with chronic low back pain on long-term opioid therapy was found to have a mixed pattern of central and obstructive apneas on his in-lab sleep study. CPAP improved the obstructive events but increased his central apnea index, a classic presentation of treatment-emergent complex sleep apnea. His sleep physician switched him to adaptive servo-ventilation (his ejection fraction was normal at 60 percent), and his pain management specialist began a gradual opioid taper with non-opioid alternatives. Within four months, his combined Apnea-Hypopnea Index dropped below 5, sleep fragmentation decreased, and his sleep efficiency improved from 68 percent to 84 percent. He tracked his metabolic biomarkers through Dumbo Health to ensure the opioid taper and improved sleep were reflected in measurable biological improvements.

A 55-year-old executive with no cardiac history and no opioid use was diagnosed with idiopathic central sleep apnea after reporting persistent fatigue and brain activity disruptions including poor concentration. Polysomnography showed a central Apnea-Hypopnea Index of 22 with no obstructive events. His sleep specialist started acetazolamide at 250 mg nightly and supplemental oxygen. Over eight weeks, the central apnea index fell to 7 and his slow oscillation and slow wave sleep percentages improved. He added the Circadian and Stress add-on pack to his Dumbo Health membership to track cortisol, providing data his neurologist also found useful at follow-up.

KEY TAKEAWAY: Central sleep apnea treatment looks different for every patient depending on the underlying cause, ejection fraction, medication history, and co-existing conditions, which is why a one-size-fits-all approach to non-CPAP alternatives fails.

These real scenarios illustrate why a comparison of all available options helps clarify the right path forward.

Comparing Non-CPAP Central Sleep Apnea Treatments

The following structured comparison covers the main non-CPAP central sleep apnea treatment options across the decision-relevant attributes that matter most when choosing a therapy.

Mechanism of Action

• Adaptive Servo-Ventilation: Delivers variable positive airway pressure breath-by-breath to prevent central apneas and stabilize ventilation
• Remede System (Phrenic Nerve Stimulation): Electrically stimulates the phrenic nerve to maintain diaphragmatic contraction during sleep
• Acetazolamide: Lowers the apneic threshold via carbonic anhydrase inhibition, widening the CO2 reserve
• Supplemental Oxygen: Prevents oxygen desaturation that triggers arousal and ventilatory overshoot
• Positional Therapy / Sleep Optimization: Reduces fluid shift and arousal frequency to stabilize breathing patterns
• Cardiac Optimization: Treats the heart failure driving Cheyne-Stokes respiration, reducing central apnea events indirectly

Heart Failure Safety

• Adaptive Servo-Ventilation: Contraindicated if ejection fraction is at or below 45 percent
• Remede System: No ejection fraction restriction; studied in heart failure patients
• Acetazolamide: Generally safe but requires metabolic monitoring; limited evidence in heart failure central sleep apnea
• Supplemental Oxygen: Safe in heart failure; commonly used as adjunct
• Positional Therapy: Safe; head elevation reduces rostral fluid shift
• Cardiac Optimization: First-line for heart failure-related central sleep apnea

Invasiveness

• Adaptive Servo-Ventilation: Non-invasive; uses a mask similar to CPAP
• Remede System: Surgical implant; requires procedure and periodic follow-up
• Acetazolamide: Oral medication; non-invasive
• Supplemental Oxygen: Non-invasive; nasal cannula during sleep
• Positional Therapy: Non-invasive; no device required
• Cardiac Optimization: Varies; medications are non-invasive, devices and surgery are invasive

Evidence Strength

• Adaptive Servo-Ventilation: Strong evidence for efficacy in non-heart-failure central sleep apnea and complex sleep apnea
• Remede System: Moderate evidence from FDA pivotal trial; limited long-term data
• Acetazolamide: Moderate evidence; mostly small studies and off-label use
• Supplemental Oxygen: Moderate evidence; American Academy of Sleep Medicine recognizes it as a treatment option
• Positional Therapy: Limited evidence for central sleep apnea specifically; more evidence for obstructive events
• Cardiac Optimization: Strong evidence that improving cardiac function reduces Cheyne-Stokes breathing

Best For

• Adaptive Servo-Ventilation: Idiopathic central sleep apnea, complex sleep apnea, central sleep apnea in patients with preserved cardiac function
• Remede System: Moderate to severe central sleep apnea in patients who fail or cannot tolerate any PAP therapy
• Acetazolamide: High-altitude central sleep apnea, idiopathic central sleep apnea, and as adjunct therapy
• Supplemental Oxygen: Central sleep apnea with prominent hypoxemia, particularly in heart failure patients who cannot use adaptive servo-ventilation
• Positional Therapy: Adjunct for any central sleep apnea type, especially when rostral fluid shift contributes
• Cardiac Optimization: Cheyne-Stokes respiration driven by heart failure

For most patients with central sleep apnea and no heart failure, adaptive servo-ventilation remains the strongest first-line non-CPAP option. For patients with reduced ejection fraction, the combination of cardiac optimization plus supplemental oxygen, with Remede System evaluation for refractory cases, represents the most evidence-supported pathway.

KEY TAKEAWAY: No single non-CPAP treatment is best for all central sleep apnea; the right choice depends on ejection fraction status, underlying cause, severity, and whether the patient can tolerate mask-based or implantable therapies.

Before committing to any treatment path, testing a few commonly repeated claims against the evidence helps avoid costly mistakes.

Common Myths About Central Sleep Apnea Treatment Debunked

MYTH: CPAP is the standard treatment for central sleep apnea, just like it is for obstructive sleep apnea.

FACT: CPAP is the gold standard for obstructive sleep apnea but can worsen central sleep apnea by lowering carbon dioxide below the apneic threshold. According to the American Academy of Sleep Medicine, treatment-emergent central sleep apnea occurs in 5 to 15 percent of patients placed on CPAP for obstructive events. Central sleep apnea requires therapies that stabilize respiratory signaling, not just airway patency.

MYTH: Oral appliances and Mandibular Advancement Devices can treat central sleep apnea if the patient cannot tolerate CPAP.

FACT: Mandibular Advancement Devices, MADs, and Tongue Retaining Devices reposition the jaw or tongue to prevent airway obstruction. Because central sleep apnea involves no airway obstruction, these devices do not address the underlying problem. They may help with the obstructive component of mixed apnea, but the central events will persist.

MYTH: Inspire therapy (hypoglossal nerve stimulation) works for central sleep apnea because it stimulates a nerve.

FACT: Inspire therapy stimulates the hypoglossal nerve, which controls the tongue, to prevent airway collapse. It is FDA-cleared only for obstructive sleep apnea. The nerve-stimulation device designed for central sleep apnea is the Remede System, which targets the phrenic nerve controlling the diaphragm. These are two completely different nerve pathways treating two completely different problems.

MYTH: If your sleep apnea is central, there is nothing you can do without wearing a mask.

FACT: Multiple mask-free options exist for central sleep apnea, including the Remede System implant, acetazolamide medication, supplemental oxygen via nasal cannula, cardiac optimization, opioid management, positional therapy, and weight reduction. The specific option depends on the cause and severity of the central apneas.

MYTH: A home sleep apnea test is enough to diagnose and plan treatment for central sleep apnea.

FACT: Most home sleep apnea tests measure airflow and oxygen but lack the respiratory effort sensors, electrocardiogram channels, and brain activity monitoring (EEG) needed to distinguish central from obstructive events accurately. The American Academy of Sleep Medicine recommends in-lab polysomnography for the definitive diagnosis of central sleep apnea. A home test through Dumbo Health (available in Florida, Texas, Virginia and Maryland) can be an effective first screening step at $149, but if central sleep apnea is suspected, in-lab follow-up is essential.

KEY TAKEAWAY: Many patients and even some providers conflate obstructive and central sleep apnea treatments, but the two conditions require fundamentally different approaches, and using the wrong therapy can worsen central events.

Correcting these misconceptions leads to a clearer understanding of how central sleep apnea connects to something most patients never consider: biological aging.

How Central Sleep Apnea Accelerates Biological Aging and Why Biomarker Tracking Matters

Central sleep apnea accelerates biological aging through chronic intermittent hypoxia, sleep fragmentation, sympathetic nervous system activation, and systemic inflammation, all of which leave measurable traces in blood biomarkers.

The Biological Aging Pathway

Every central apnea event triggers a brief drop in oxygen levels, followed by an arousal that fragments sleep architecture. This pattern repeats dozens or hundreds of times per night in severe cases. According to the NIH, intermittent hypoxia increases oxidative stress and activates inflammatory pathways, driving up markers like hs-CRP and interleukin-6. The repeated sympathetic surges from arousals elevate cortisol, raise blood pressure, and stress the cardiovascular system.

Over months and years, this nightly insult shows up as accelerated biological aging. Metabolic markers deteriorate. Cardiovascular risk markers climb. Inflammatory markers stay elevated. The cumulative damage is not hypothetical. It is measurable.

SleepLongevityAge: Connecting Sleep to Biological Age

Dumbo Health's proprietary SleepLongevityAge metric is built from blood biomarkers and optional wearable data from devices like Oura, Whoop, and Garmin. It calculates a biological age score that reflects how your sleep quality, or sleep disorders like central sleep apnea, are shifting your aging trajectory relative to your chronological age.

For someone with central sleep apnea, tracking SleepLongevityAge over time provides objective evidence of whether treatment is reversing the biological damage caused by years of disrupted breathing. A decrease in SleepLongevityAge after starting adaptive servo-ventilation, acetazolamide, or cardiac optimization is a tangible signal that treatment is working at a level deeper than symptom relief.

The Core plan at $0.99 a day tests 51 sleep-longevity biomarkers twice a year through the Quest Diagnostics network, with more than 2,000 locations nationwide and roughly 9 in 10 people living within 20 minutes of a draw site. Blood draws are also available through in-home mobile phlebotomists in select states. The Concierge plan at $300 a month includes 103 biomarkers, a dedicated sleep physician with 24/7 access, a personal sleep coach, and all add-on specialty packs.

What Biomarkers to Watch When You Have Central Sleep Apnea

Central sleep apnea affects specific biomarker clusters that map directly to longevity research:

• Cardiovascular markers: NT-proBNP (available through the Cardiac Strain add-on at $429), ApoB, lipoprotein(a)
• Inflammatory markers: hs-CRP, ferritin
• Metabolic markers: HbA1c, fasting glucose, insulin
• Hormonal markers: cortisol (available through the Circadian and Stress add-on at $269), DHEA-S, testosterone
• Kidney function: GFR, creatinine, especially important if on acetazolamide

These are not abstract research endpoints. They are the markers that move when central sleep apnea is treated successfully, and they are the markers that stay elevated when treatment is inadequate. Tracking them gives you and your physicians an objective, data-driven view of whether your treatment plan is protecting your long-term health, not just improving tonight's sleep study numbers.

All plans are HSA and FSA eligible, require no insurance and no prior authorizations, and early-member pricing at $0.99 a day locks for life for the first 500 members.

TIP: If you are starting a new central sleep apnea treatment, consider drawing baseline biomarkers before initiating therapy. A pre-treatment SleepLongevityAge score gives you a reference point to measure improvement against at your six-month retest.

KEY TAKEAWAY: Central sleep apnea causes measurable biological aging through inflammation, hypoxia, and sympathetic activation, and longitudinal biomarker tracking through a platform like Dumbo Health converts treatment progress from subjective symptom reports into objective data.

Conclusion

Central sleep apnea treatment without CPAP is not only possible but often necessary, because CPAP can worsen the very breathing instability it is supposed to fix. The right path forward depends on whether your central apneas are driven by heart failure, opioid use, altitude, or an idiopathic chemoreflex instability, and each cause maps to a different treatment ranging from adaptive servo-ventilation to the Remede System to acetazolamide to cardiac optimization. What ties every pathway together is the need for accurate diagnosis through in-lab polysomnography and longitudinal monitoring that shows whether treatment is actually protecting your long-term health. Dumbo Health's sleep longevity membership tracks the biomarkers most affected by central sleep apnea, starting at $0.99 a day, with no insurance required, HSA and FSA eligible, and early-member pricing locked for life for the first 500 members.

Frequently Asked Questions About Central Sleep Apnea Treatment Without CPAP

What is central sleep apnea?

Central sleep apnea is a sleep disorder in which the brain temporarily fails to send the correct signals to the respiratory muscles that control breathing during sleep. Unlike obstructive sleep apnea, which involves a physical airway blockage, central sleep apnea occurs because the brainstem does not reliably regulate breathing effort. The result is repeated pauses in breathing, drops in oxygen levels, sleep fragmentation, and disrupted sleep quality. According to the American Academy of Sleep Medicine, central sleep apnea can occur independently or alongside obstructive sleep apnea, and in some cases the two overlap in what is called complex sleep apnea.

What are the symptoms of central sleep apnea?

Central sleep apnea symptoms include waking up short of breath, excessive daytime sleepiness, difficulty staying asleep, morning headaches, poor concentration, and mood changes. Some people notice a pattern of abnormal breathing during sleep called Cheyne-Stokes breathing, where breathing cycles between very deep breaths and complete pauses. A bed partner may observe that breathing stops during sleep. Because symptoms overlap with other sleep disorders, a proper sleep study is needed to distinguish central sleep apnea from obstructive sleep apnea or other causes of disrupted sleep.

What causes central sleep apnea?

Central sleep apnea is caused by instability in the brain's control of breathing, particularly in the brainstem regions that regulate respiratory drive. Common underlying causes include heart failure, stroke, kidney failure, high-altitude exposure, opioid pain medications, and neurological conditions. A key mechanism in many forms of central sleep apnea is hypocapnia, where carbon dioxide levels fall below the threshold needed to trigger a breath, causing the respiratory system to pause. Cheyne-Stokes respiration, which is closely associated with heart disease, is one of the most recognised patterns of hypocapnic central sleep apnea. A physician can help identify the specific underlying cause.

What are the risk factors for central sleep apnea?

Risk factors for central sleep apnea include heart disease, previous stroke, use of opioid pain medications, high-altitude sleeping environments, obesity, being male, and being over the age of 60. Heart failure is one of the most significant risk factors because it can destabilise the respiratory chemoreflex and carbon dioxide regulation during sleep. People with complex sleep apnea, which is a mixed apnea pattern that emerges during CPAP therapy for obstructive sleep apnea, may also be at risk. The American Academy of Sleep Medicine recommends that people with known cardiovascular disease who have sleep symptoms be evaluated by a sleep specialist.

How is central sleep apnea diagnosed?

Central sleep apnea is diagnosed through a sleep study, most commonly an in-lab polysomnography test. Polysomnography monitors brain activity, oxygen levels, airflow, respiratory effort, heart rhythm via electrocardiogram, and body position throughout the night. The key diagnostic difference between central and obstructive sleep apnea is that central events show no respiratory effort during the breathing pause, while obstructive events show continued effort against a blocked airway. The Apnea-Hypopnea Index measures the frequency of events per hour. A sleep specialist or physician interprets the polysomnographic results and determines whether central sleep apnea is present and what is causing it.

Can central sleep apnea be treated without CPAP?

Yes, central sleep apnea can be treated without CPAP in many cases, depending on the underlying cause, severity, and individual response to alternative therapies. Treatment options include adaptive servo-ventilation, Bilevel Positive Airway Pressure therapy, supplemental oxygen, acetazolamide, transvenous phrenic nerve stimulation using devices such as the Remede System, treatment of underlying heart failure or other contributing conditions, and reduction or elimination of opioid medications where clinically appropriate. Not every alternative is suitable for every patient, and a sleep specialist or physician should guide treatment decisions based on a complete evaluation.

What is adaptive servo-ventilation and when is it used for central sleep apnea?

Adaptive servo-ventilation, often abbreviated as ASV, is a form of positive airway pressure therapy that automatically adjusts pressure support breath by breath to stabilise breathing patterns. It is designed specifically for complex sleep apnea and certain forms of central sleep apnea, particularly those involving Cheyne-Stokes respiration. ASV differs from standard CPAP by actively responding to changes in breathing effort rather than delivering a fixed or auto-titrated pressure. Importantly, clinical guidelines from the American Academy of Sleep Medicine advise against ASV in patients with symptomatic heart failure and a significantly reduced ejection fraction, as evidence suggests it may increase cardiovascular risk in that specific group. A cardiologist or sleep physician should assess suitability.

What is Bilevel Positive Airway Pressure therapy and how does it differ from CPAP?

Bilevel Positive Airway Pressure therapy, commonly known as BiPAP or BPAP, delivers two separate pressure levels: a higher pressure during inhalation and a lower pressure during exhalation. This makes breathing feel more natural compared to the continuous fixed pressure of CPAP. For central sleep apnea, BiPAP with a timed backup breath rate can help prompt breathing when the brain fails to initiate a respiratory signal. BiPAP is often used when patients cannot tolerate CPAP or when the sleep specialist determines that pressure support rather than pressure stabilisation is the appropriate treatment approach. BiPAP is a type of PAP machine and still requires a mask and pressurised air.

What is the Remede System and how does it treat central sleep apnea?

The Remede System is an implantable device approved by the Food and Drug Administration that treats central sleep apnea through transvenous phrenic nerve stimulation. It works by sending electrical signals to the phrenic nerve, which controls the diaphragm, prompting the diaphragm to contract and initiate a breath when the brain fails to do so. The device is implanted under the skin near the collarbone and monitors breathing continuously during sleep. It is generally considered for moderate to severe central sleep apnea in patients who have not responded adequately to other treatments. A cardiothoracic or electrophysiology team typically performs the implantation procedure.

Can oxygen therapy treat central sleep apnea?

Supplemental oxygen can reduce central sleep apnea events in some patients, particularly those with heart failure-related Cheyne-Stokes respiration or high-altitude central sleep apnea. Oxygen therapy works partly by raising blood oxygen levels and may help stabilise the respiratory chemoreflex, reducing the CO2 reserve instability that drives hypocapnic central apnea. However, supplemental oxygen does not address airway obstruction, does not suit every type of central sleep apnea, and is not a substitute for treating the underlying cause. A sleep physician or pulmonologist should evaluate whether supplemental oxygen is appropriate and at what flow rate, since unmonitored oxygen use carries its own risks.

What medications are used to treat central sleep apnea without CPAP?

Acetazolamide is the medication most frequently used in the management of central sleep apnea as a non-PAP option. It is a carbonic anhydrase inhibitor that works by inducing mild metabolic acidosis, which stimulates ventilation and helps stabilise the respiratory chemoreflex, particularly in high-altitude central sleep apnea and some hypocapnic central sleep apnea syndromes. Theophylline has also been studied in certain patient groups. Carbon dioxide inhalation approaches, such as Enhanced Expiratory Rebreathing Space therapy, target CO2 reserve instability directly. All medication decisions should be made by a qualified physician who can weigh the risks, benefits, and interactions with existing health conditions, particularly heart disease.

What is the Enhanced Expiratory Rebreathing Space approach for central sleep apnea?

Enhanced Expiratory Rebreathing Space, abbreviated as EERS, is an approach that increases the amount of exhaled carbon dioxide that is rebreathed during sleep. By raising end-tidal CO2 levels slightly, EERS helps keep carbon dioxide above the apnea threshold and can reduce the frequency of central apnea events caused by hypocapnia. This approach attempts to address one of the core mechanisms of hypocapnic central sleep apnea without requiring pressurised airway therapy. It remains a developing treatment approach and is not yet widely available as a standardised clinical product. A sleep physician should be consulted to determine whether this method is clinically appropriate.

Can treating underlying heart disease reduce central sleep apnea?

Yes, treating the underlying condition causing central sleep apnea often reduces or resolves the breathing disruptions. In heart failure patients, optimising cardiac medications, managing fluid overload, and improving cardiac output can meaningfully reduce Cheyne-Stokes respiration and central sleep apnea severity. The Cleveland Clinic and other major cardiac centres recognise this connection and often coordinate care between cardiologists and sleep specialists for patients with both heart failure and central sleep apnea. Simply treating the sleep apnea without addressing the cardiac cause is unlikely to produce lasting improvement. A cardiologist and sleep physician should manage these conditions together.

How can opioid medications cause central sleep apnea and what can be done?

Opioid pain medications suppress the brainstem's respiratory drive, which can produce or worsen central sleep apnea. Opioid-induced central sleep apnea often presents with an irregular or ataxic breathing pattern rather than the typical Cheyne-Stokes pattern seen in cardiac patients. Reducing or discontinuing opioids, when medically safe and appropriate, can improve or resolve the central apnea. This decision must always involve the prescribing physician, a pain management specialist, or a relevant clinician, and should never be made independently. For patients who cannot reduce opioids, a sleep specialist can evaluate alternative breathing support options. Stopping opioids abruptly without medical supervision is not safe.

What is complex sleep apnea and how is it treated?

Complex sleep apnea, sometimes called treatment-emergent central sleep apnea, occurs when central sleep apnea events appear or become prominent after CPAP therapy begins for obstructive sleep apnea. During CPAP use, the obstructive events resolve, but the device unmasks an underlying tendency toward central events that may not have been apparent before treatment. In many cases, complex sleep apnea resolves on its own within weeks of continued CPAP therapy as the respiratory system adapts. When it persists, a sleep physician may consider switching to adaptive servo-ventilation, BiPAP with backup rate, or another treatment approach. Ongoing monitoring is important because the condition can evolve.

Are oral appliances effective for central sleep apnea?

Oral appliances such as Mandibular Advancement Devices are generally more effective for obstructive sleep apnea than for central sleep apnea. They work by repositioning the lower jaw and tongue to prevent airway collapse, which addresses an obstructive mechanism rather than the neurological failure of respiratory signalling that drives central events. In mixed apnea cases or complex sleep apnea with a strong obstructive component, a Mandibular Advancement Device may reduce the obstructive contribution and indirectly improve overall sleep quality. A sleep specialist should confirm the predominant type of apnea before recommending oral appliance therapy, since it may not adequately treat pure central sleep apnea.

Is hypoglossal nerve stimulation an option for central sleep apnea?

Hypoglossal nerve stimulation, such as the Inspire therapy system, is currently approved by the Food and Drug Administration specifically for moderate to severe obstructive sleep apnea and is not approved as a primary treatment for central sleep apnea. The device works by stimulating the hypoglossal nerve to move the tongue forward during sleep, preventing airway obstruction. Because central sleep apnea involves a failure of respiratory signalling rather than a physical airway blockage, hypoglossal nerve stimulation does not address the core mechanism. Patients with mixed apnea who have a significant obstructive component may be evaluated on a case-by-case basis, but a sleep physician must confirm candidacy.

Can positional therapy help with central sleep apnea?

Positional therapy, which involves training or preventing the body from sleeping in certain positions, is primarily used for position-dependent obstructive sleep apnea. Central sleep apnea is generally not driven by body position in the way obstructive events often are, so positional therapy alone is unlikely to be a sufficient treatment for most central apnea cases. However, in patients with mixed apnea or complex sleep apnea where obstructive events are also present, improving sleep position may reduce the obstructive component. A sleep specialist can determine whether a positional approach is worth incorporating into a broader treatment plan after a thorough evaluation.

What happens if central sleep apnea is left untreated?

Untreated central sleep apnea is associated with significant health risks. Repeated drops in oxygen levels during sleep can strain the cardiovascular system, worsen heart failure, raise blood pressure, disrupt heart rhythm, and impair cognitive function over time. Sleep fragmentation from frequent arousals reduces slow wave sleep and overall sleep quality, contributing to daytime sleepiness, mood disturbance, and reduced alertness. For people with underlying heart disease, untreated central sleep apnea may accelerate cardiovascular deterioration. The relationship is bidirectional, with heart disease worsening central apnea and central apnea worsening heart disease. A healthcare professional should be consulted to discuss the individual risks of delaying or avoiding treatment.

Can you live a long healthy life with central sleep apnea?

Many people with central sleep apnea manage the condition effectively and live full lives, particularly when the underlying cause is identified and treated appropriately. Outcomes depend heavily on the severity of the apnea, the nature of the underlying condition, how well treatment is tolerated, and how consistently care is followed. According to the National Heart, Lung, and Blood Institute, sleep disorders that go untreated can contribute to cardiovascular and metabolic health problems over time, so active management matters. With appropriate treatment, physician monitoring, and management of co-existing conditions such as heart failure or obesity, the long-term outlook for many patients is meaningfully improved.

How does central sleep apnea affect cardiovascular health?

Central sleep apnea and cardiovascular disease have a closely linked, bidirectional relationship. Heart failure is one of the leading causes of Cheyne-Stokes breathing and central apnea, while the repeated oxygen desaturations and autonomic stress caused by central apnea events can in turn worsen cardiac function. Each apnea event triggers a surge in sympathetic nervous system activity, raises heart rate and blood pressure acutely, and over time may contribute to arrhythmia, worsened heart failure, and reduced cardiac output. Neurologists, cardiologists, and sleep specialists often need to coordinate care for patients in whom central sleep apnea and heart disease coexist, since treating one condition in isolation may not produce adequate results.

What questions should I ask my doctor about central sleep apnea treatment?

Useful questions to ask your healthcare provider include: How do you know I have central sleep apnea rather than obstructive sleep apnea? What is most likely causing my central sleep apnea? What treatment do you recommend, and why is it appropriate for my situation? How long will I need treatment? Are there non-CPAP options that suit my condition and lifestyle? How will we monitor whether treatment is working? What happens if my symptoms change? How should I manage my sleep apnea alongside my other health conditions, such as heart disease or hypertension? A prepared conversation with your clinician helps ensure your treatment plan is personalised and evidence-based.

How common is central sleep apnea compared to obstructive sleep apnea?

Central sleep apnea is significantly less common than obstructive sleep apnea. The American Academy of Sleep Medicine describes central sleep apnea as accounting for a small minority of diagnosed sleep apnea cases, while obstructive sleep apnea is far more prevalent. Central sleep apnea is more likely to be identified in people with heart failure, neurological conditions, or opioid use, and it is sometimes discovered only after CPAP therapy reveals treatment-emergent central events. Because it is less common, many primary care settings have less immediate experience with it, making referral to a sleep specialist particularly important for accurate diagnosis and treatment selection.

How does a home sleep apnea test relate to central sleep apnea diagnosis?

Home sleep apnea tests, also called home sleep tests or HSATs, are widely used for diagnosing obstructive sleep apnea but have important limitations for central sleep apnea. Most HSAT devices measure airflow, oxygen saturation, respiratory effort, and heart rate, but they do not record brain activity, which is necessary for definitively characterising central versus obstructive events. If a home sleep test result is abnormal or if central sleep apnea is clinically suspected, a physician will typically recommend a full in-lab polysomnography study to obtain the detail needed to confirm the diagnosis and guide treatment. A clinician can advise whether a home test or an in-lab study is the appropriate starting point for your situation.

How does sleep apnea testing and care work at Dumbo Health?

Dumbo Health offers a $149 at-home sleep apnea test that is FDA-cleared, purchased before the test night, and billed separately from any membership. The test is available in Florida, Texas, Virginia and Maryland and is designed to identify obstructive sleep apnea patterns, with physician diagnosis typically available within 48 hours. If CPAP is indicated, Dumbo Health offers a separate CPAP plan in those states from $59 a month, including the machine, a mask fitted to your face, resupply and a care team. Dumbo Health does not treat central sleep apnea. For people who want to understand how sleep is affecting their biological health more broadly, Dumbo Health's sleep longevity membership includes biomarker panels, SleepLongevityAge tracking, and physician support. Everything is cash-pay with no insurance required, and the Core and Concierge memberships are HSA and FSA eligible.

Can biomarker testing reveal how central sleep apnea may be affecting my health?

Biomarker testing cannot diagnose central sleep apnea, but certain blood markers can reflect the metabolic, inflammatory, and cardiovascular stress that untreated sleep apnea may be contributing to over time. Markers such as hs-CRP for inflammation, HbA1c for metabolic health, cortisol for stress response, and cardiovascular risk markers such as ApoB can provide a broader picture of how disrupted sleep may be influencing biological aging and organ function. Dumbo Health's Core and Concierge membership plans test 51 or 103 sleep-longevity biomarkers twice a year and combine results into a SleepLongevityAge score. A physician can help interpret what the results mean for your individual health.

Where can I find a blood draw location for sleep longevity biomarker testing?

Dumbo Health works with a network of testing locations for at-home or nearby blood draws as part of its sleep longevity membership. You can find a testing location near you using the location finder on the Dumbo Health website. Testing is designed to be convenient, with results reviewed by physicians and incorporated into your SleepLongevityAge score and personalised guidance. If you are unsure whether biomarker testing or sleep apnea testing is the right starting point, the free Dumbo Health sleep quiz can help clarify the appropriate next step.

Is there a free way to assess whether I may need sleep apnea or longevity testing?

Yes. Dumbo Health offers a free sleep quiz that helps you identify whether biomarker testing, at-home sleep apnea testing, or a broader sleep longevity programme may be a reasonable next step for your situation. The quiz is not a clinical diagnosis and does not replace evaluation by a healthcare professional, but it can provide useful initial guidance. You can take the free sleep quiz on the Dumbo Health website. If you have severe symptoms, chest pain, significant shortness of breath, or urgent health concerns, seek prompt medical care rather than starting with an online quiz.